ABSTRACT: Viscosupplementation (VS) is still controversial. One of the key points is the lack of well-identified factors of response. We aimed to identify clinical and radiological factors associated with lack of relevant response after intra-articular (IA) hyaluronic acid (HA) injections in symptomatic knee osteoarthritis patients. A post hoc analysis of the HAV-2012 trial, a controlled, multicentre, double-blind, randomized, non-inferiority trial comparing 3 weekly IA injections of HA (HAnox-M or BioHA) for symptomatic tibiofemoral OA was performed. At inclusion, demographic, anthropometric, clinical data (WOMAC score, patient global assessment, presence of knee effusion), and radiological data (OARSI grade, patello-femoral involvement) were recorded. VS response was defined according to OMERACT-OARSI response criteria at month 6. Predictors of response were investigated in univariate then in multivariate analysis. One hundred and sixty-six patients with full available data were included. As baseline characteristics and treatment effectiveness were similar between the 2 HA groups, their data were pooled. The mean age was 65.2 [63.7-66.8] years; 101 (60.8%) were women; 73 (44.0%) had severe TF space narrowing. At 6 months, 113 patients (68.1%) were responders. Multivariate analysis showed that obesity (BMI 30 kg/m 2) and radiological severity (OARSI grade 3) were significantly associated with VS failure (p ¼ 0.001 and p ¼ 0.008, respectively). Moreover, the association of obesity and severe TF space narrowing significantly increased the risk of VS failure. Baseline pain intensity and functional impairment were not associated with VS response. Consequently, IA injection of HA for knee OA should mainly be considered in subjects with low BMI and mild TF space narrowing. ß
Viscosupplementation (VS), or intra-articular (IA) injection of hyaluronic acid (HA), is widely used for knee osteoarthritis (OA). Nevertheless, the recommendations from international scientist societies (ACR, 1 EULAR, 2 OARSI, 3 AAOS 4 ) remain unclear and somewhat contradictory, which leads to confusion for clinicians. This is due to the heterogeneous results and conclusions of meta-analyses regarding VS. Some international experts have expressed reservations or disagreements about these recommendations [5] [6] [7] because of the gap between meta-analyses results and their clinical experience. Nonetheless, uncertainties remain about the use of VS in knee OA given the variability of HA intrinsic properties (animal origin or not, molecular weight, concentration, cross-linking, etc.), the IA injection protocol (fluoroscopy or ultrasound guidance, 1-5 weekly injections), the OA phenotype and clinical or radiological severity.
Concerning these latter factors, a closer selection of VS eligible patients could optimize the results. Thus, as emphasized by many experts, identifying predictive factors of VS outcome could help clinicians to define the patients who would best benefit from VS. Altman et al. studied in a multicentre, randomized trial the differential response to hyaluronan compared to placebo at 26 weeks in different subgroups of knee OA patients divided according to their anthropometric (sex, age, BMI), clinical (symptom severity, IA effusion), and radiological (severity) characteristics. Mild differences were observed without statistical significance. 8 Another study highlighted the positive impact on self-reported satisfaction after Hylan GF-20 injection of the following factors: Moderate effusion, injection lateral to the patella, joint space loss in a single compartment, and radiological meniscal calcinosis. 9 Otherwise, a meta-analysis of randomized controlled trials reported radiographic severity associated with poor HA response. 10 A recent analysis from the database of the FLEXX trial (double blind, randomized saline-controlled trial assessing the efficacy of Euflexxa) confirmed the negative impact of radiographic severity on VS response.
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The HAV-2012 study, a prospective, multicenter, randomized, non-inferiority trial comparing 2 HA products in symptomatic knee OA, provided the opportunity to study the association between baseline patient characteristics and response to HA at 6 months. 12 We aimed to identify the demographic, anthropometric, clinical or radiological factors associated with VS response according to OMERACT-OARSI criteria in patients with symptomatic knee OA.
MATERIALS AND METHODS

Characteristics of the HAV-2012 Trial (Level I)
The HAV-2012 study was a prospective, double-blind, randomized, multicenter, parallel-group trial, conducted in 26 centers in France between October 2012 and April 2014 (registration no. EudraCT 2012-A00570-43). 12 The aim of the study was to compare the efficacy and safety of 3 weekly injections of HANOX-M (HAppyVisc
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, LABRHA SAS, Lyon, France), combining sodium hyaluronate (1-1.5 MDa, 31 mg/2 ml) with mannitol 3.5%, to a proven, effective, and well-tolerated HA viscosupplement, BioHA (Euflexxa 1 , Ferring Pharmaceuticals, Parsippany, 2.4-3.6 MDa, 20 mg/2 ml), in patients with symptomatic knee OA. The study was performed in compliance with the principles of Good Clinical Practice (GCP) and the Declaration of Helsinki concerning medical research in humans and the country-specific regulations. Before enrolment, patients were required to sign an informed consent form and were free to withdraw at any time for any reason. The patient informed consent form and the protocol, which complied with the requirements of the International Conference on Harmonization (ICH), were reviewed and approved by the Ethics Committee of Lyon Sud-Est IV.
Study Design and Patients
All details of the study design and inclusion criteria were described previously. 12 Briefly, the study included males and females, aged 40-85 years, fulfilling the ACR criteria for knee OA 13 who failed to respond or were intolerant to analgesics and/or non-steroidal anti-inflammatory drugs (NSAIDs) or weak opioids and who had self-assessed their walking pain from 3 to 8 on a 11-point Likert scale (0-10) at baseline. Bilateral knee X-rays were performed within the 3 previous months and included the following incidences: Standing posteroanterior view, Lyon-schuss view, lateral view, and skyline incidence of the patella. Investigators assessed the OARSI score 14 for tibiofemoral (TF) joint space narrowing (JSN) (grade 0 ¼ normal; grade 1 ¼ mild JSN; grade 2 ¼ moderate JSN; and grade 3 ¼ severe JSN) and Kellgren-Lawrence (KL) score 15 on the radiological view highlighting the most severe lesions. The presence of patellafemoral (PF) OA was also assessed. To be included, patients had to have an OARSI radiological score for TF JSN of 1-3 and so a KL grade of 3 or 4. Only the most painful joint (target knee) was treated and assessed, but patients with bilateral knee OA could be included if walking pain score for the contralateral knee was <3. The main exclusion criteria were OA flare with Knee OA Flare-Ups Score >7, 16 tibial plateau or femoral condyle bone attrition, symptomatic hip OA or any other active inflammatory or microcrystal rheumatic disease, excessive varus or valgus knee misalignment (8˚), VS in the target knee within the previous 9 months, and systemic/IA corticosteroids use within the previous 3 months. The following concomitant medications for knee OA were allowed: Acetaminophen (up to 4 g/day), weak opioids (tramadol, codeine), analgesic doses of ibuprofen (daily dose 800 mg) and naproxen (daily dose <500 mg), topical NSAIDs, and symptomatic slow-acting drugs for OA (glucosamine, chondroitin sulfate, diacerhein, or avocado/ soya unsaponifiables) if started at least 2 months before screening and not substantially altered during the study. IA corticosteroids were permitted only for joints other than the target knee. NSAIDs at anti-inflammatory doses, strong opioids, systemic corticosteroids, IA corticosteroids, and viscosupplements into the target knee were prohibited throughout the follow-up. Patients were asked to discontinue analgesic therapy 48 h before each evaluation visit.
Patients were randomized to one of the following treatment groups: HAnox-M or Bio-HA in a 1:1 ratio by blocks of four treatments, balanced 2:2. The intent-to-treat (ITT) population included all subjects who were randomized, fulfilled the inclusion/exclusion criteria, received at least one injection of HAnox-M or BioHA and had at least one post-baseline evaluation.
Baseline and Follow-Up Examination
At the screening visit, demographic data (age, sex), anthropometric data (height, weight, and BMI), medical history (disease duration), and treatments for knee OA (especially analgesics and NSAIDs) were recorded. Obesity was defined as BMI 30 kg/m 2 . Other investigations included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and patient global assessment at baseline, at the time of each injection on weeks (W) 1-3, then at the follow-up visits at W12 and W26. WOMAC evaluates OA health status and outcomes with 24 questions 17 summarized as a total WOMAC score and pain, stiffness, and physical function subscores. Each question is answered with a 5-point Likert scale (0 ¼ none, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe, 4 ¼ extreme), with a maximal score of 96 for the total score (20 for pain, 8 for stiffness, and 68 for physical function subscores). Each score was also converted to a 100-point scale, lower scores indicating better status. Patient global assessment evaluating the disease activity was self-assessed with a 10-point Likert scale (1-10) and converted to a 100-point scale. IA effusion was clinically assessed before each injection by experienced physicians (orthopedic surgeon or rheumatologist).
The relative changes in WOMAC score and patient global assessment at 6 months compared to baseline were calculated as (baseline value -6 month value)/baseline value. According to the criteria published by Pham et al., 18 the OMERACT-OARSI response was defined as a decrease 50% and an absolute change 20 points in WOMAC pain or function score or by a decrease 20% and an absolute change 10 points in at least two of the following factors: WOMAC pain, WOMAC function, patient global assessment.
Treatments Under Study Both viscosupplements, HAnox-M (HAppyVisc
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) and Bio-HA (Euflexxa 1 ), were supplied in 2 ml syringes containing 2 ml HA solution. They were administered without ultrasound or fluoroscopy guidance, 1 week apart, for 3 consecutive weeks, into the target knee by parapatellar approach via a 18-to 21-gauge needle by an experienced physician, who was not blinded to treatment and who was different from the clinical evaluator. If present, synovial fluid was removed prior each injection. A significant effusion was defined as the aspiration of more than 5 ml prior at least one of the three injections. The patient and the clinical evaluator were both blinded to treatment throughout the follow-up.
Statistical Analysis
Baseline and 6-month follow-up characteristics are presented as number (%) or mean [95%CI] . A Mann-Whitney or a chi-square was used to assess the association of quantitative or qualitative factors and OMERACT-OARSI response with VS. Multivariate logistic regression analysis was used to identify predictors of OMERACT-OARSI response and included sex, age, symptoms outcomes at baseline (patient global assessment, WOMAC pain and function), and other factors with p < 0.20 on univariate analysis. p < 0.05 was considered statistically significant. XLSTAT 2015 (Addinsoft) was used for statistical analysis. 
RESULTS
Patient Characteristics at Baseline and Clinical Outcomes 6 Months After VS
In total, 226 patients were initially randomized, but 21 were excluded from the ITT analysis because they did not meet inclusion/exclusion criteria. Complete data for WOMAC pain and function, and patient global assessment allowing the assessment OMERACT-OARSI response at 6 months were available for 166 patients (Fig. 1) . Demographic data are presented in Table 1 A trend toward association with VS failure was also noted for older age (p ¼ 0.158). Sex, disease duration, symptom characteristics at baseline (patient global assessment, WOMAC pain and function), radiological PF OA or analgesic intake did not influence achieving of a OMERACT-OARSI response after VS (Table 3) . Similarly, IA effusion evidenced by clinical exam or defined as the aspiration of synovial fluid prior at least one of the three HA injections but also the presence of a significant effusion (5 ml Finally, we noted a significant cumulative impact of these two factors on VS response. Indeed, only 41.7% of obese patients with a severe TF space narrowing had a relevant response to VS as compared to 87.1% of nonobese patients with a mild or moderate space narrowing (Fig. 2) 
DISCUSSION
Our study, based on a prospective, controlled, randomized trial responding to a consort statement for well-performed clinical trials, is one of the first to specifically assess predictors of clinical response after VS. Indeed, only one analysis with a specific design to study predictive factors of HA efficacy was previously published by Altman et al. from the FLEXX database. We showed that higher BMI (or obese status) and greater TF JSN were the two main predictors of VS failure according to OMERACT-OARSI criteria with a specific impact of each factor but also a statistically significant impact of their accumulation. The negative impact of OA severity on VS outcome has been already suggested by the meta-analysis published by Wang et al. 10 and the recent analysis from the FLEXX database. 11 Moreover, this finding is consistent with the results of a previous study showing an inverse relation between VS effectiveness and initial levels of several catabolic biomarkers measured in synovial fluid reflecting OA severity. 19 In contrast, this study is the first to show a link between obesity and VS response. Indeed, the likelihood of obtaining a relevant response after VS decreased significantly with increasing BMI. We cannot exclude the bias related to the increased risk of extra-articular HA injection related to larger para-patellar adipose tissue. Nonetheless, the mean BMI of patients was rather low (27.7 kg/m 2 ) as compared with that in the typical knee OA population. 20, 21 Moreover, BMI and VS response were correlated in the whole population whereas this latter included a majority of nonobese patients (71.7%) without large parapatellar adipose tissue. Consequently, the involvement of adipose tissue thickness is less probable. Further studies are necessary to compare VS effectiveness depending on weight status with an accurate IA placement based on echographic or radiological guidance. However, in real life, HA injection is primarily performed without fluoroscopy or ultrasound guidance, so the potential impact of overweight/obesity on VS response should already be taken into account for clinical practice.
Our study also showed that combination of obesity and OA radiological severity increased the likelihood of not achieving a relevant response after VS. Therefore, their association in a patient should really lead the clinician to question about the benefit/risk balance of VS. In our best knowledge, no previous studies had described such a cumulative impact of predictive factors on VS response.
Our study has some limitations. First, this was a post hoc analysis, not included in the initial design of the HAV-2012 trial. Furthermore, as a non-inferiority trial, it included two distinct groups of patients receiving 2 different HA formulations. However, we found no significant differences between baseline characteristics of each population and similar results were found for each IA HA. 12 Furthermore, the data for determining OMERACT-OARSI response (WOMAC function and pain scores, and patient global assessment) were available for only 166 of the 205 patients in the ITT population. Thus, we cannot exclude a selection bias due to these missing data. Analgesics (acetaminophen, weak opioids, analgesic doses of ibuprofen, and naproxen) were allowed during this trial, which may be a concern in terms of clinical response to VS. However, this treatment is close to our daily practice, in which VS is considered in addition to analgesics level 1 and 2. Although radiological meniscal calcinosis has been previously highlighted as a potential predictive factor of VS response, this radiological data was not assessed in HAV-2012 trial because was not a radiological inclusion or exclusion criteria.
Our study also has several strengths. First, compared to observational, retrospective study, the controlled, randomized design of HAV-2012 trial allowed for a more rigorous data collection. Furthermore, in the context of controversy regarding the effect of HA, this is the first study identifying the predictors PREDICTIVE FACTORS OF VISCOSUPPLEMENTATION of a relevant response based on a validated outcome (OMERACT-OARSI criteria). To conclude, TF JSN severity according to OARSI score and obesity may be predictors of lack of a relevant response after VS. Moreover, although previous targetknee HA or corticosteroid injection and age >65 years were not significantly associated with a relevant response, their combination with obesity and radiological severity could also have a negative impact on the VS response. In contrast, disease duration and symptom severity did not alter the response to VS. Thus, a more stringent selection of patients eligible for HA injection could optimize the effectiveness of treatment and limit the number of VS injections in those with risk factors for poor outcome. This finding may impact our daily practice and help in considering VS in future international recommendations.
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